Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics.

[1]  P. Heagerty,et al.  Diabetes and CKD in the United States Population, 2009-2014. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[2]  M. Woodward,et al.  Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. , 2017, The lancet. Diabetes & endocrinology.

[3]  P. Heagerty,et al.  Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. , 2016, JAMA.

[4]  Alan B Leichtman,et al.  US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  A. Cheung,et al.  GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  T. Stijnen,et al.  Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[7]  I. D. de Boer,et al.  Diabetic Kidney Disease: A Report From an ADA Consensus Conference , 2014, Diabetes Care.

[8]  B. Zinman,et al.  Longitudinal changes in estimated and measured GFR in type 1 diabetes. , 2014, Journal of the American Society of Nephrology : JASN.

[9]  I. D. de Boer.  Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study , 2013, Diabetes Care.

[10]  Toshiyuki Shimizu,et al.  A nonclassical vitamin D receptor pathway suppresses renal fibrosis. , 2013, The Journal of clinical investigation.

[11]  M. D. de Borst,et al.  Active vitamin D treatment for reduction of residual proteinuria: a systematic review. , 2013, Journal of the American Society of Nephrology : JASN.

[12]  I. D. de Boer,et al.  Impaired vitamin D metabolism in CKD. , 2013, Seminars in nephrology.

[13]  M. Woodward,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.

[14]  D. Deb,et al.  Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[15]  B. Zinman,et al.  Circulating vitamin D metabolites and kidney disease in type 1 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[16]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[17]  J. Manson,et al.  The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. , 2012, Contemporary clinical trials.

[18]  A. Rule,et al.  The impact of interlaboratory differences in cystatin C assay measurement on glomerular filtration rate estimation. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[19]  B. Kestenbaum,et al.  Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[20]  Patrick J Heagerty,et al.  Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.

[21]  P. Singer,et al.  Effects of polyunsaturated fatty acid consumption in diabetic nephropathy , 2011, Nature Reviews Nephrology.

[22]  C. Rosen.  Clinical practice. Vitamin D insufficiency. , 2011, The New England journal of medicine.

[23]  Christine L. Taylor,et al.  Committee to Review Dietary Reference Intakes for Vitamin D and Calcium , 2011 .

[24]  Ingrid Zegers,et al.  First certified reference material for cystatin C in human serum ERM-DA471/IFCC , 2010, Clinical chemistry and laboratory medicine.

[25]  Chun-Ka Wong,et al.  Fish‐oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[26]  L. Appel,et al.  The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. , 2009, The American journal of clinical nutrition.

[27]  S. Mulroney,et al.  Omega-3 fatty acid rich diet prevents diabetic renal disease. , 2009, American journal of physiology. Renal physiology.

[28]  D. Bruns,et al.  Current issues in measurement and reporting of urinary albumin excretion. , 2009, Clinical chemistry.

[29]  G. Ning,et al.  Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase , 2008, Proceedings of the National Academy of Sciences.

[30]  Judith Wylie-Rosett,et al.  Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee , 2006, Circulation.

[31]  Y. Tomino,et al.  Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[33]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[34]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[35]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .